Folia Biologica
Journal of Cellular and Molecular Biology, Charles University 

Individual author index pages

• Jana Šímová
• M. Reiniš
• V. Sobota
• J. Čapková
• J. Bubeník
• T. Jandlová

Other articles of these authors

• Serum Levels of Matrix Metalloproteinases 2 and 9 in Patients with Acute Myocardial Infarction

  Jana Šímová, J. Škvor, D. Slovák, I. Mazura, J. Zvárová

  2013, Vol. 59, Issue 5, pp. 181-187
• Serum Levels of Matrix Metalloproteinases 2 and 9 and TGFBR2 Gene Screening in Patients with Ascending Aortic Dilatation

  Jana Šímová, J. Škvor, J. Reissigová, J. Dudra, J. Lindner, P. Čapek, J. Zvárová

  2013, Vol. 59, Issue 4, pp. 154-161
• Genetically Modified Vaccines Augment the Efficacy of Cancer Surgery and Chemotherapy

  J. Bubeník

  2009, Vol. 55, Issue 6, pp. 199-200
• Immunotherapeutic Efficacy of Vaccines Generated by Fusion of Dendritic Cells and HPV16-Associated Tumour Cells

  Jana Šímová, J. Bubeník, J. Bieblová, M. Indrová, T. Jandlová

  2005, Vol. 51, Issue 1, pp. 19-24
• Immunogenicity of Dendritic Cell-Based HPV16 E6/E7 Peptide Vaccines: CTL Activation and Protective Effects

  Marie Indrová, M. Reiniš, J. Bubeník, T. Jandlová, J. Bieblová, V. Vonka, J. Velek

  2004, Vol. 50, Issue 6, pp. 184-193
• The Role of NK1.1⁺ Cells in the Protection against MHC Class I⁺ HPV16-Associated Tumours

  Jana Šímová, J. Bubeník, J. Bieblová, T. Jandlová

  2004, Vol. 50, Issue 6, pp. 200-202
• Adjuvant Cytokine Treatment of Minimal Residual Disease after Surgical Therapy in Mice Carrying HPV16-Associated Tumours: Cytolytic Activity of Spleen Cells from Tumour Regressors

  Marie Indrová, R. Mikyšková, T. Jandlová, V. Vonka, J. Bubeník, J. Bieblová

  2003, Vol. 49, Issue 6, pp. 217-222
• MHC Class I⁺ and Class I^- HPV16-Associated Tumours Expressing the E7 Oncoprotein Do Not Cross-react in Immunization/Challenge Experiments

  Jana Šímová, R. Mikyšková, V. Vonka, J. Bieblová, J. Bubeník, T. Jandlová

  2003, Vol. 49, Issue 6, pp. 230-234
• Immunotherapy of HPV 16-Associated Tumours with Tumour Cell Line/Dendritic Cell Line (TC-1/DC2.4) Hybrid Vaccines

  Jana Šímová, J. Bieblová, T. Jandlová, J. Bubeník

  2003, Vol. 49, Issue 5, pp. 203-206
• Local IFN-γ Therapy of HPV16-Associated Tumours

  Romana Mikyšková, J. Bieblová, J. Šímová, M. Indrová, T. Jandlová, V. Vonka, M. Šmahel, J. Bubeník, L. Mendoza

  2003, Vol. 49, Issue 1, pp. 26-32
• Freezing and Thawing of Murine Bone Marrow-Derived Dendritic Cells Does Not Alter Their Immunophenotype and Antigen Presentation Characteristics

  Luis Mendoza, J. Bubeník, M. Indrová, J. Bieblová, V. Vonka, J. Šímová

  2002, Vol. 48, Issue 6, pp. 242-245
• Tumour-Inhibitory Effects of Dendritic Cells Administered at the Site of HPV 16-Induced Neoplasms

  Luis Mendoza, J. Bubeník, J. Šímová, J. Korb, J. Bieblová, V. Vonka, M. Indrová, R. Mikyšková, T. Jandlová

  2002, Vol. 48, Issue 3, pp. 114-119
• Intratumoral IL-2 Gene Transfer Improves the Therapeutic Efficacy of IL-12 but Not IL-18

  V. Sobota, Jan Bubeník, J. Šímová, T. Jandlová

  2000, Vol. 46, Issue 5, pp. 191-193
• Peritumoral Administration of Antigen-Unstimulated Bone Marrow-Derived Dendritic Cells Inhibits Tumour Growth

  Luis Mendoza, M. Indrová, R. Hájková, M. Reiniš, M. Šmahel, V. Vonka, J. Bubeník, T. Jandlová

  2000, Vol. 46, Issue 3, pp. 91-97